Tisotumab Vedotin Demonstrates Survival Benefit in Chinese Cervical Cancer Subpopulation
• Tisotumab vedotin significantly improved overall survival compared to chemotherapy in Chinese patients with previously treated recurrent or metastatic cervical cancer.
• The antibody-drug conjugate reduced the risk of death by 45% in the Chinese subpopulation, consistent with global trial results.
• Zai Lab plans to submit a new drug application to China's National Medical Products Administration based on these findings.
• The results offer hope for addressing the unmet need for effective treatments after relapse, including after anti-PD-(L)1 therapy.
© Copyright 2025. All Rights Reserved by MedPath